Public Health Service Guidelines for the Management of Possible Sexual, Injecting-Drug-Use, or Other Nonoccupational Exposure to HIV, Including Considerations Related to Antiretroviral Therapy
September 25, 1998
Surveillance of Documented Exposures
CDC will request follow-up information on patients whose nonoccupational HIV exposure is documented and who gave consent to their physician for data reporting. CDC also will assist with HIV testing when asked.
Unusual or severe toxicity from antiretroviral drugs should be reported to the manufacturer or the Food and Drug Administration (-332-1088). The use of antiretroviral drugs for pregnant women should be reported (without patient identifiers) to the Antiretroviral Pregnancy Registry (-258-4263).
For further information about the CDC-sponsored External Consultants Meeting on Antiretroviral Therapy for Potential Nonoccupational Exposures to HIV, which took place in July, 1997, contact the National AIDS Clearinghouse (-458-5231 or the Internet website.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication Morbidity and Mortality Weekly Report. Visit the CDC's website to find out more about their activities, publications and services.